ATE421883T1 - Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline - Google Patents

Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline

Info

Publication number
ATE421883T1
ATE421883T1 AT99969030T AT99969030T ATE421883T1 AT E421883 T1 ATE421883 T1 AT E421883T1 AT 99969030 T AT99969030 T AT 99969030T AT 99969030 T AT99969030 T AT 99969030T AT E421883 T1 ATE421883 T1 AT E421883T1
Authority
AT
Austria
Prior art keywords
glucan
compositions containing
specific immunoglobulins
containing beta
beta
Prior art date
Application number
AT99969030T
Other languages
English (en)
Inventor
Viliam Pavliak
Ali Fattom
Robert Naso
Original Assignee
Nabi Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi Biopharmaceuticals filed Critical Nabi Biopharmaceuticals
Application granted granted Critical
Publication of ATE421883T1 publication Critical patent/ATE421883T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
AT99969030T 1998-09-14 1999-09-14 Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline ATE421883T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10014698P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
ATE421883T1 true ATE421883T1 (de) 2009-02-15

Family

ID=22278313

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99969030T ATE421883T1 (de) 1998-09-14 1999-09-14 Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline

Country Status (11)

Country Link
US (1) US6355625B1 (de)
EP (1) EP1121135B1 (de)
AT (1) ATE421883T1 (de)
AU (1) AU6033299A (de)
CA (1) CA2344166C (de)
CY (1) CY1109437T1 (de)
DE (1) DE69940371D1 (de)
DK (1) DK1121135T3 (de)
ES (1) ES2321892T3 (de)
PT (1) PT1121135E (de)
WO (1) WO2000015238A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US7030101B2 (en) * 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
WO2002058711A1 (en) 2001-01-16 2002-08-01 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
CN100363054C (zh) * 2002-09-04 2008-01-23 生物聚合物工程有限公司 全葡聚糖颗粒在抗癌药物中的应用
US20090169557A1 (en) * 2004-05-10 2009-07-02 Biopolymer Engineering, Inc. D/B/A Biothera Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies
EP2305294B1 (de) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogene Zusammensetzung zur Verwendung zur Impfung gegen Staphylokokken
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
EP1850867A1 (de) * 2005-01-10 2007-11-07 Nabi Biopharmaceuticals Verfahren zur behandlung einer infektion mit staphylococcus aureus
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
US20090214562A1 (en) * 2005-05-03 2009-08-27 Karel Steven J Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
US20060263415A1 (en) * 2005-05-05 2006-11-23 Sensient Flavors Inc. Production of beta-glucans and mannans
KR101302764B1 (ko) 2005-06-13 2013-09-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 포도상구균 감염을 치료 및 예방하기 위한 팬톤-발렌타인류코시딘의 용도
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
NZ574057A (en) 2006-06-12 2012-01-12 Glaxosmithkline Biolog Sa Staphylococcal antigen composition comprising an isolated S. aureus type 5 antigen; an isolated S. aureus type 8 antigen; an isolated S. aureus 336 antigen; an isolated S. aureus alpha-toxin antigen; and an isolated Staphylococcal leukocidin antigen
EP2208787A1 (de) 2009-01-19 2010-07-21 Université de Liège Rekombinantes alpha-Hämolysin-Polypeptid von Staphylococcus aureus, mit einer Deletion in der Stammdomäne und eingefügten heterologen Sequenzen
WO2010085590A1 (en) 2009-01-23 2010-07-29 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
PT3281947T (pt) 2009-04-03 2020-05-07 Univ Chicago Composições e métodos relacionados com variantes da proteína a (spa)
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2555794A4 (de) 2010-04-05 2014-01-15 Univ Chicago Zusammensetzungen und verfahren im zusammenhang mit protein-a-(spa)-antikörpern als immunreaktionsverstärker
KR102050078B1 (ko) 2010-05-05 2019-11-28 뉴욕 유니버시티 스타필로코커스 아우레우스 류코시딘, 치료 조성물 및 그것의 용도
SG186290A1 (en) 2010-07-02 2013-01-30 Univ Chicago Compositions and methods related to protein a (spa) variants
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
BR122020000047B1 (pt) 2011-06-19 2021-04-13 New York University Composições compreendendo proteína luke isolada ou polipeptídeo da mesma, uma proteína lukd isolada ou polipeptídeo da mesma ou sua combinação, bem como seu uso
EP3135339A1 (de) 2011-06-19 2017-03-01 New York University Leukotoxin e/d als neuer entzündungshemmer und mikrobizid
EP2744517B1 (de) 2011-08-15 2019-03-13 The University of Chicago Zusammensetzungen und verfahren in zusammenhang mit antikörpern gegen das staphylokokken-protein a
EP2844275B1 (de) 2012-04-26 2020-05-13 University of Chicago Staphylokokken-coagulase-antigene und verfahren zu deren verwendung
JP6251730B2 (ja) 2012-04-26 2017-12-20 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法
US11229701B2 (en) * 2012-04-30 2022-01-25 Hibercell, Inc. Methods for identifying beta-glucan binding to immune cells
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
BE1023004A1 (fr) 2014-12-10 2016-10-31 Glaxosmithkline Biologicals Sa Procede de traitement
JP7117244B2 (ja) 2016-02-12 2022-08-12 ザ・ユニバーシティ・オブ・シカゴ 黄色ブドウ球菌疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法
US11815435B2 (en) 2017-02-24 2023-11-14 Hibercell, Inc. Beta glucan immunopharmacodynamics
IL291821A (en) 2019-10-02 2022-06-01 Janssen Vaccines & Prevention Bv Staphylococcus peptides and methods of use
WO2023192998A1 (en) 2022-04-01 2023-10-05 Icahn School Of Medicine At Mount Sinai Treating orthopedic injury with a vector driving expression of acid ceramidase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4900722A (en) * 1985-08-19 1990-02-13 Bioglucans, L.P. Methods and compositions for prophylactic and therapeutic treatment of infections
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
CA2040374C (en) * 1990-07-06 1998-06-16 Gunnar Rorstad Process for enhancing the resistance of aquatic animals to disease
ATE237351T1 (de) * 1991-11-22 2003-05-15 Univax Biolog Inc Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i
WO1996014873A2 (en) 1994-11-16 1996-05-23 Sri International COVALENTLY BOUND β-GLUCAN CONJUGATES IN TARGETED DELIVERY
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen

Also Published As

Publication number Publication date
AU6033299A (en) 2000-04-03
CA2344166A1 (en) 2000-03-23
ES2321892T3 (es) 2009-06-12
CA2344166C (en) 2008-11-18
US6355625B1 (en) 2002-03-12
DK1121135T3 (da) 2009-03-23
CY1109437T1 (el) 2014-08-13
DE69940371D1 (de) 2009-03-19
EP1121135B1 (de) 2009-01-28
WO2000015238A9 (en) 2000-10-12
PT1121135E (pt) 2009-03-05
WO2000015238A1 (en) 2000-03-23
WO2000015238B1 (en) 2000-08-31
EP1121135A4 (de) 2005-03-16
EP1121135A1 (de) 2001-08-08

Similar Documents

Publication Publication Date Title
DE69940371D1 (de) Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
BR9917152A (pt) Composição para tratamento terapêutico ou profilático de infecção estreptocócica e método e uso respectivos
NO965378D0 (no) Pyrazolo- og pyrolopyridiner
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
TR200000059T2 (tr) Piridin türevleri
ATE251942T1 (de) Stapelbare statische mischelemente
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
TR199900856T2 (xx) Bron�la ilgili terapi maddeleri olarak benzonaftiridinler
DE69928952D1 (de) Chinolin-derivate und ihre verwendung als antibakterielle wirkstoffe
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
ES2191208T3 (es) Oxiimino-pregnano-carbolactonas.
ATE355288T1 (de) Verbindungen und therapeutische methoden
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
DK1042492T3 (da) Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
BRPI0413684A (pt) compostos, composição farmacêutica e respectivos métodos de preparação, de tratamento de infecção microbiana e de extermìnio de microrganismo e usos
DE69931784D1 (de) Chemotaxis hemmendes protein von staphylococcus aureus (chips) und dessen verwendung
BR0308734A (pt) Composto, composição farmacêutica, uso do composto, e, método para prevenir ou tratar infecção
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.
ATE212839T1 (de) Hämoregulatorische verbindungen
IT1276454B1 (it) Metodo per la diagnosi di infezioni helycobacter pylori e relativo corredo diagnostico.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1121135

Country of ref document: EP